Trial Profile
Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ETBX 021 (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors NantBioScience
- 23 Aug 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified September 2018 ).
- 23 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2018 Status changed from active, no longer recruiting to recruiting.